首页> 外文期刊>Therapeutic Drug Monitoring >Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids
【24h】

Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids

机译:测试非传统基质以监测海洛因,可卡因,安非他明,合成阴茎和合成阿片类药物的产前暴露

获取原文
获取原文并翻译 | 示例
       

摘要

Background: The prevalence of drug use during pregnancy continues to increase despite the associated serious adverse obstetrical outcomes, including increased risk of miscarriage, fetal growth restriction, brain development impairment, neonatal abstinence syndrome, preterm delivery, and stillbirths. Monitoring drug use during pregnancy is crucial to limit prenatal exposure and provide suitable obstetrical health care. The authors reviewed published literature reporting the concentrations of common drugs of abuse and new psychoactive substances (NPS), such as synthetic cathinones and synthetic opioids, NPS, and their metabolites using unconventional matrices to identify drug use during pregnancy and improve data interpretation. Methods: A literature search was performed from 2010 to July 2019 using PubMed, Scopus, Web of Science scientific databases, and reports from international institutions to review recently published articles on heroin, cocaine, amphetamine, methamphetamine, synthetic cathinone, and synthetic opioid monitoring during pregnancy. Results: Meconium has been tested for decades to document prenatal exposure to drugs, but data regarding drug concentrations in amniotic fluid, the placenta, the umbilical cord, and neonatal hair are still lacking. Data on prenatal exposure to NPS are limited. Conclusions: Maternal hair testing is the most sensitive alternative matrix for identifying drug use during pregnancy, while drug concentrations in the meconium, placenta, and umbilical cord offer the identification of prenatal drug exposure at birth. Adverse developmental outcomes for the infant make it critical to promptly identify maternal drug use to limit fetal exposure or, if determined at birth, to provide resources to the exposed child and family. Alternative matrices offer choices for monitoring and challenge laboratories to deliver highly sensitive and specific analytical methods for detection.
机译:背景:尽管存在严重的严重不良产科结果,但怀孕期间药物使用的患病率持续增加,包括流产风险增加,胎儿生长限制,脑发展障碍,新生儿禁欲综合征,早产和死产。监测怀孕期间的药物使用对于限制产前暴露并提供合适的产科保健至关重要。作者审查了已发表的文献,报告了使用非传统基质的合成天然粘液和合成阿片类药物,NPS和它们代谢物等滥用滥用和新的精神活性物质(NPS)的浓度,以识别怀孕期间的药物使用,并改善数据解释。方法:从2010年到2019年7月,使用PubMed,Scopus,科学数据库网络进行了文学搜索,以及国际机构的报告,以便在海洛因,可卡因,安非他明,甲基苯丙胺,合成显膜和合成阿片类药物期间进行审查最近公布的文章怀孕。结果:几十年来测试了梅诺伊,以对药物进行产前暴露,但有关羊水中的药物浓度,胎盘,脐带和新生毛发的数据仍然缺乏。对NPS产前暴露的数据有限。结论:母体毛发检测是妊娠期间识别药物使用的最敏感的替代基质,而MeConium,胎盘和脐带的药物浓度则提供出生时的产前药物暴露的鉴定。对婴儿的不利发展结果使迅速识别母体药物用于限制胎儿暴露或在出生时确定,为暴露的儿童和家庭提供资源。替代矩阵提供监测和挑战实验室的选择,以提供高度敏感和特异性分析方法进行检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号